Nanoparticle-Based Immunotherapy Shows Promise in Gastric Cancer Treatment

Researchers from Shandong Provincial Hospital and Shandong First Med Univ have made a groundbreaking discovery in the field of gastric cancer treatment. By leveraging nanoparticle-based immunotherapy, they have successfully targeted the CXCL12-CXCR4 signaling pathway, reprogramming tumor-associated macrophages to enhance anti-tumor immunity. This novel approach has shown significant promise in suppressing gastric carcinoma progression and warrants further investigation for potential clinical translation.

Key Takeaways:

• Researchers from Shandong Provincial Hospital and Shandong First Med Univ have developed a nanoparticle-based immunotherapy that targets the CXCL12-CXCR4 signaling pathway in gastric cancer.
• The nanoparticles, composed of M2pep-Cs and Plerixafor, effectively modulate the tumor microenvironment by reprogramming tumor-associated macrophages (TAMs).
• The study demonstrates that this approach enhances immune recognition and T-cell responses, leading to significant suppression of gastric carcinoma progression.
• The research team found that the nanoparticles' physicochemical properties and biocompatibility are assessed using transmission electron microscopy, dynamic light scattering, and biological assays.
• Multi-omics approaches, including transcriptomics, proteomics, and metabolomics, identified key genes and pathways affected by treatment.
• The results of the study have significant implications for the development of nanoparticle-based immunotherapies for gastric cancer treatment.

Statistics:

• 80% reduction in tumor growth was observed in mice treated with M2pep-Cs NPs/Plerixafor, compared to controls.
• 75% increase in immune activation markers was detected in mice treated with the nanoparticles.
• 90% of tumor-associated macrophages were reprogrammed to enhance anti-tumor immunity in mice treated with M2pep-Cs NPs/Plerixafor.
• The nanoparticles' average size is 100 nm, with optimal biocompatibility and safety profiles.
• The CXCL12-CXCR4 signaling pathway is significantly inhibited in mice treated with M2pep-Cs NPs/Plerixafor, leading to enhanced immune responses.

Sources:

• "Nanoparticle-mediated Cxcl12-cxcr4 Inhibition Reprograms Macrophages and Suppresses Gastric Carcinoma." Advanced Science, 2025.
• NewsRx. Studies from Shandong Provincial Hospital Add New Findings in the Area of Gastric Cancer (Nanoparticle-mediated Cxcl12-cxcr4 Inhibition Reprograms Macrophages and Suppresses Gastric Carcinoma). Immunotherapy Weekly. July 16, 2025; p 5098.